The current first-line treatments for recurrent or metastatic prostate cancer are hormone therapies, including those that target androgen receptor (AR) signaling such as bicalutamide, and drugs such as gonadotropin-releasing hormone agonists that prevent androgen production in the testicles and adrenal glands. This evidence concerns the gene AR and metastatic prostate carcinoma.